Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 11/20 | 1.00 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 1.00 |
| ▸ | DHFR known ✓ | P00374 | 4/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 7/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 6/20 | 1.00 |
| ▸ | FOLR2 | P14207 | 3/20 | 1.00 |
| ▸ | ATIC | P31939 | 2/20 | 1.00 |
| ▸ | SHMT1 | P34896 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL5959741 | 1.00 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL209720 | 1.00 | GART (1.00) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL14321276 | 0.99 | GART (0.98) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| Pemetrexed SCHEMBL1933381 | 0.99 | GART (0.98) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL24846092 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967346 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL15078815 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967345 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL22967367 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS | |
| SCHEMBL29710616 | 0.97 | GART (0.93) | GARTFOLR1SLC46A1SLC19A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259513-B1 | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR | LILLY CO ELI (US) | 2003-09-10 | — | — | EP | claimed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| WO-2021026310-A1 | PROCESSES OF PREPARING POLYGLUTAMATED ANTIFOLATES AND USES OF THEIR COMPOSITIONS | L.E.A.F. HOLDINGS GROUP LLC (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20200323992-A1 | MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2020-10-15 | — | — | US | disclosed |
| US-10736969-B2 | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds | NEKTAR THERAPEUTICS (US) | 2020-08-11 | — | — | US | disclosed |
| US-9765079-B2 | Crystalline forms of pemetrexed diacid and manufacturing processes therefor | SCINTOPHARM TAIWAN, LTD. (TW) | 2017-09-19 | — | — | US | disclosed |
| US-20170253597-A9 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | SCINOPHARM TAIWAN, LTD. (TW) | 2017-09-07 | — | — | US | disclosed |
| US-20170121334-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | SCINOPHARM TAIWAN LTD (TW) | 2017-05-04 | — | — | US | disclosed |
| US-9604990-B2 | Crystalline forms of pemetrexed diacid and manufacturing processes therefor | SCINOPHARM TAIWAN, LTD. (TW) | 2017-03-28 | — | — | US | disclosed |
| EP-2882753-B1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN CHEMIE AG (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20160122355-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | SCINOPHARM TAIWAN, LTD. (TW) | 2016-05-05 | — | — | US | disclosed |
| WO-2016059238-A1 | PEMETREXED FORMULATIONS | TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY (HU) | 2016-04-21 | — | — | WO | disclosed |
| EP-2882753-A1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN-CHEMIE AG (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014024164-A1 | PROCESS FOR THE PREPARATION OF PEMETREXED AND LYSIN SALT THEREOF | BERLIN-CHEMIE AG (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253597-A9 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | DCTD, DPYD, TYMP | GART 14/4885TYMS 4/4885DHFR 8/4885 |
| US-20170121334-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | DCTD, DPYD, TYMP | GART 14/4885TYMS 4/4885DHFR 8/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | GART 3960/4885TYMS 2929/4885DHFR 1829/4885 |
| US-10736969-B2 | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds | PAICS, MTHFD2, MTHFD1 | GART 56/4885TYMS 14/4885DHFR 5/4885 |
| US-20160122355-A1 | CRYSTALLINE FORMS OF PEMETREXED DIACID AND MANUFACTURING PROCESSES THEREFOR | DCTD, DPYD, TYMP | GART 14/4885TYMS 4/4885DHFR 8/4885 |
| US-20200323992-A1 | MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS | PAICS, MTHFD2, MTHFD1 | GART 56/4885TYMS 14/4885DHFR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.